株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

掻痒症治療薬の世界市場:2019年~2023年

Global Pruritus Drugs Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 891083
出版日 ページ情報 英文 143 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
掻痒症治療薬の世界市場:2019年~2023年 Global Pruritus Drugs Market 2019-2023
出版日: 2019年07月12日 ページ情報: 英文 143 Pages
概要

掻痒治療薬は、皮膚または全身性疾患に伴うかゆみを治療するために使用されます。2018年には、血液掻痒セグメントが最も高い市場シェアを獲得しましたが、腫瘍性掻痒セグメントは、掻痒を引き起こす腫瘍学的徴候の増加により、予測期間にわたって市場シェアの点で先行する見通しです。ほとんど全ての種類の癌では、患者が掻痒症を発症するリスクが高くなります。また、世界の掻痒治療薬市場は、免疫療法選好の高まりおよび慢性疾患の罹患率の上昇などが成長要因となり、予測期間中に5%以上のCAGRで拡大する見込みです。しかしながら、代替療法の利用可能性、複雑な病因、および患者アドヒアランスの低さが、予測期間にわたる掻痒治療薬産業の成長を妨げる可能性があります。

当レポートでは、世界の掻痒症治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 パイプライン

第7章 市場セグメンテーション:アプリケーション別

  • 市場セグメンテーション:アプリケーション別
  • アプリケーション別比較:市場規模および予測(2018年~2023年)
  • 血液掻痒
  • 腫瘍性掻痒症
  • 腎掻痒症
  • 内分泌掻痒症
  • 胆汁掻痒
  • 市場機会:アプリケーション別

第8章 市場セグメンテーション:投与ルート別

第9章 顧客情勢

第10章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第13章 市場動向

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Allergan Plc
  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

第16章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第17章 TECHNAVIOについて

図表
  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Global pruritus drugs market pipeline: Overview
  • Exhibit 19: Global pruritus drugs market pipeline: Snapshot
  • Exhibit 20: Application - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by application
  • Exhibit 22: Hematologic pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Hematologic pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Oncological pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Oncological pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Renal pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Renal pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Endocrine pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Endocrine pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Cholestatic pruritus - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Cholestatic pruritus - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Market opportunity by application
  • Exhibit 33: RoA - Market share
  • Exhibit 34: Few prominent topical drugs
  • Exhibit 35: Customer landscape
  • Exhibit 36: Market share by geography 2018-2023 (%)
  • Exhibit 37: Geographic comparison
  • Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in North America
  • Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in Europe
  • Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 46: Top 3 countries in Asia
  • Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 49: Top 3 countries in ROW
  • Exhibit 50: Key leading countries
  • Exhibit 51: Market opportunity
  • Exhibit 52: Indications that are associated with pruritus
  • Exhibit 53: Impact of drivers and challenges
  • Exhibit 54: Vendor landscape
  • Exhibit 55: Landscape disruption
  • Exhibit 56: Vendors covered
  • Exhibit 57: Vendor classification
  • Exhibit 58: Market positioning of vendors
  • Exhibit 59: Allergan Plc - Vendor overview
  • Exhibit 60: Allergan Plc - Business segments
  • Exhibit 61: Allergan Plc - Organizational developments
  • Exhibit 62: Allergan Plc - Geographic focus
  • Exhibit 63: Allergan Plc - Segment focus
  • Exhibit 64: Allergan Plc - Key offerings
  • Exhibit 65: Allergan Plc - Key customers
  • Exhibit 66: Astellas Pharma Inc. - Vendor overview
  • Exhibit 67: Astellas Pharma Inc. - Business segments
  • Exhibit 68: Astellas Pharma Inc. - Organizational developments
  • Exhibit 69: Astellas Pharma Inc. - Geographic focus
  • Exhibit 70: Astellas Pharma Inc. - Key offerings
  • Exhibit 71: Astellas Pharma Inc. - Key customers
  • Exhibit 72: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 73: GlaxoSmithKline Plc - Business segments
  • Exhibit 74: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 75: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 76: GlaxoSmithKline Plc - Segment focus
  • Exhibit 77: GlaxoSmithKline Plc - Key offerings
  • Exhibit 78: GlaxoSmithKline Plc - Key customers
  • Exhibit 79: Pfizer Inc. - Vendor overview
  • Exhibit 80: Pfizer Inc. - Business segments
  • Exhibit 81: Pfizer Inc. - Organizational developments
  • Exhibit 82: Pfizer Inc. - Geographic focus
  • Exhibit 83: Pfizer Inc. - Segment focus
  • Exhibit 84: Pfizer Inc. - Key offerings
  • Exhibit 85: Pfizer Inc. - Key customers
  • Exhibit 86: Sanofi - Vendor overview
  • Exhibit 87: Sanofi - Business segments
  • Exhibit 88: Sanofi - Organizational developments
  • Exhibit 89: Sanofi - Geographic focus
  • Exhibit 90: Sanofi - Segment focus
  • Exhibit 91: Sanofi - Key offerings
  • Exhibit 92: Sanofi - Key customers
  • Exhibit 93: Validation techniques employed for market sizing
  • Exhibit 94: Definition of market positioning of vendors
目次
Product Code: IRTNTR31704

About this market

Pruritus drugs are used to treat itches associated with skin or systemic diseases. Technavio's pruritus drugs market analysis considers sales from the topical, oral, and parenteral segments. The market is also segmented based on application into hematologic pruritus, oncological pruritus, renal pruritus, endocrine pruritus, and cholestatic pruritus. Our analysis also considers the sales of pruritus drugs in Asia, Europe, North America, and ROW. In 2018, the hematologic pruritus segment held the highest market share. However, the oncological pruritus segment will lead in terms of market share over the forecast period owing to rising oncological indications that cause pruritus. Almost all types of cancers put patients at increased risk of developing pruritus. Also, our global pruritus drugs report has observed market growth factors such as the growing preference for immunotherapy and rising prevalence of chronic diseases. However, the availability of alternative therapies, complex pathogenesis, and poor patient adherence may hamper the growth of the pruritus drugs industry over the forecast period.

Overview

Growing preference for immunotherapy

The rising use of immunotherapy drugs to treat oncological indications is increasing the incidence of pruritus. As a result, the demand for pruritus drugs such as topical emollients, antihistamines, and topical corticosteroids is increasing. The high efficacy of immunotherapy in treat cancer is not allowing patients to withdraw from the treat. Therefore, the growing preference for immunotherapy will help market vendors in increasing sales. This will contribute to the growth of the global pruritus drugs market at over 5% CAGR during the forecast period.

Nanoparticle-enabled transdermal drug delivery systems

Transdermal drug delivery is not effective in the delivery of small and lipophilic drugs. As a result, vendors have come up with nanoparticle-enabled transdermal drug delivery systems, which provide faster onset of action. They are also less painful compared with routes that require incisions. Moreover, biodegradable nanoparticles can prolong the duration of drug adhesion. These factors will increase the adoption of nanoparticle-enabled transdermal drug delivery systems, which will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global pruritus drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global pruritus drugs market is fragmented. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading Pruritus Drugs manufacturers, which include Allergan Plc, Astellas Pharma Inc., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the pruritus drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Hematologic pruritus - Market size and forecast 2018-2023
  • Oncological pruritus - Market size and forecast 2018-2023
  • Renal pruritus - Market size and forecast 2018-2023
  • Endocrine pruritus - Market size and forecast 2018-2023
  • Cholestatic pruritus - Market size and forecast 2018-2023
  • Market opportunity by application

PART 08: MARKET SEGMENTATION BY ROA

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan Plc
  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 17: EXPLORE TECHNAVIO

Back to Top